Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
Objective: To determine whether oral vitamin D supplementation reduces the risk of glucocorticoid (GC)-associated severe adverse events (SAEs) in patients with giant cell arteritis (GCA) included in the Spanish ARTESER registry.
Source: Abstract. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Eligible patients were aged ≥50 years, consistent with the epidemiology of GCA and the age threshold specified in the 1990 ACR classification criteria [], and met at least one of the following criteria: (i) a positive diagnostic test: temporal artery biopsy (TAB), ultrasound (US), or another relevant imaging modality; (ii) fulfillment of ≥3 of the 5 1990 American College of Rheumatology (ACR) classification criteria for GCA; or (iii) a clinical diagnosis of GCA by the treating physician in accordance with recent recommendations.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Can Vitamin D Reduce Glucocorticoid-Induced Adverse Effects in Patients with Giant Cell Arteritis? Results from 1568 Patients in the Spanish ARTESER Registry †
Study design awaiting verification · Nutrients · 2025
Original publication title
Can Vitamin D Reduce Glucocorticoid-Induced Adverse Effects in Patients with Giant Cell Arteritis? Results from 1568 Patients in the Spanish ARTESER Registry †
© 2025 by the authors.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Objective: To determine whether oral vitamin D supplementation reduces the risk of glucocorticoid (GC)-associated severe adverse events (SAEs) in patients with giant cell arteritis (GCA) included in the Spanish ARTESER registry. Methods: The ARTESER registry collected data from patients diagnosed with GCA across 26 Spanish public hospitals between June 2013 and March 2019. SAEs were defined as fatal, life-threatening, or requiring hospitalization. Patients were categorized according to the use or non-use of oral vitamin D supplements. Incidence rates (IRs) of SAEs were expressed per person-year with 95% confidence intervals (CIs).
Cox proportional hazards models assessed vitamin D supplementation and its interaction with cumulative glucocorticoid dose. Results: Of 1568 patients (mean age 76.9 ± 8.1 years; 70.1% women) receiving GC, 120 (7.6%) experienced SAEs (IR 0.039; 95% CI 0.033 to 0.047). Vitamin D supplementation was documented in 1186 (75.6%) compared with 382 (24.4%) non-supplemented patients. SAE incidence was similar in supplemented (n = 89; 7.5%; IR 0.038, 95% CI 0.030 to 0.046) and non-supplemented patients (n = 31; 8.1%; IR 0.045, 95% CI 0.031 to 0.064) (p = 0.387).
Multivariable Cox regression showed a significant interaction between vitamin D supplementation and cumulative glucocorticoid dose (interaction term HR 0.90; p = 0.033), consistent with a dose-dependent protective effect. Conclusions: Vitamin D supplementation was not independently associated with a lower incidence of GC-related SAEs, likely due to residual confounding factors. However, the interaction with cumulative GC exposure suggests a modulatory effect. Prospective studies incorporating stratified baseline vitamin D assessments are warranted.
Authors’ abstract
Objective: To determine whether oral vitamin D supplementation reduces the risk of glucocorticoid (GC)-associated severe adverse events (SAEs) in patients with giant cell arteritis (GCA) included in the Spanish ARTESER registry. Methods: The ARTESER registry collected data from patients diagnosed with GCA across 26 Spanish public hospitals between June 2013 and March 2019. SAEs were defined as fatal, life-threatening, or requiring hospitalization. Patients were categorized according to the use or non-use of oral vitamin D supplements. Incidence rates (IRs) of SAEs were expressed per person-year with 95% confidence intervals (CIs).
Cox proportional hazards models assessed vitamin D supplementation and its interaction with cumulative glucocorticoid dose. Results: Of 1568 patients (mean age 76.9 ± 8.1 years; 70.1% women) receiving GC, 120 (7.6%) experienced SAEs (IR 0.039; 95% CI 0.033 to 0.047). Vitamin D supplementation was documented in 1186 (75.6%) compared with 382 (24.4%) non-supplemented patients. SAE incidence was similar in supplemented (n = 89; 7.5%; IR 0.038, 95% CI 0.030 to 0.046) and non-supplemented patients (n = 31; 8.1%; IR 0.045, 95% CI 0.031 to 0.064) (p = 0.387).
Multivariable Cox regression showed a significant interaction between vitamin D supplementation and cumulative glucocorticoid dose (interaction term HR 0.90; p = 0.033), consistent with a dose-dependent protective effect. Conclusions: Vitamin D supplementation was not independently associated with a lower incidence of GC-related SAEs, likely due to residual confounding factors. However, the interaction with cumulative GC exposure suggests a modulatory effect. Prospective studies incorporating stratified baseline vitamin D assessments are warranted.
Publication and source details
Original title: Can Vitamin D Reduce Glucocorticoid-Induced Adverse Effects in Patients with Giant Cell Arteritis? Results from 1568 Patients in the Spanish ARTESER Registry †
Gastón A. Ghio; Marta Domínguez-Álvaro; Iñigo Hernández Rodríguez; Elisa Fernández-Fernández; Maite Silva-Díaz; Joaquín M. Belzunegui; Clara Moriano; Julio Sánchez Martín; Javier Narváez; Eva Galíndez Agirregoikoa; Anne Riveros Frutos; Francisco Ortiz Sanjuán; Tarek C. Salman Monte; Margarida Vasques Rocha; Carlota L. Iñiguez; Alicia García Dorta; Clara Molina Almela; María Alcalde Villar; José L. Hernández; Santos Castañeda; Ricardo Blanco
Nutrients · 2025
* Correspondence: gaghioreumatologia@gmail.comThis article is an extended and updated version of the conference abstract published in: Ghio, G.A.; Domínguez-Álvaro, M.; Rodríguez, I.H.; Fernández-Fernández, E.; Silva, M.T.; Belzunegui, J.M.; Moriano, C.; Martín, J.S.; Castañeda, S.; Blanco, R., on behalf of the ARTESER Project Collaborative Group, et al. Vitamin D Supplementation in the Prevention of Severe Adverse Effects Caused by Glucocorticoids: Study from the ARTESER Registry of Giant Cell Arteritis. In Proceedings of the ACR Convergence 2024, Washington, DC, USA, 14 to 19 November 2024.
These authors contributed equally to this work.
ARTESER Project Collaborative Group: Ismael González Fernández, Elvira Díez Álvarez, Trinidad Pérez Sandoval (Complejo Asistencial Univ. de León, León); Vicente Aldasoro Cáceres, Javier Mendizábal Mateos, María Concepción Fito Manteca, Natividad del Val del Amo, Loreto Horcada Rubio, Inmaculada Paniagua Zudaire, Laura Garrido Courel, Ricardo Gutiérrez Polo, Juliana Restrepo Vélez, Eduardo Loza Cortina (Complejo Hospitalario de Navarra, Pamplona); Patricia Carreira, Tomás Almorza (Hospital 12 de Octubre); Lydia Abasolo Alcázar, Leticia Léon Mateos, Luis Rodríguez Rodríguez, Judit Font Urgelles, Pia Mercedes Lois Bermejo (Hospital Clínico San Carlos); Selena Labrada Arrabal (Hospital de Mar); Ivette Casafont, Susana Holgado Pérez, Jordi Camins (Hospital Germans Trias i Pujol); Cristina Campos Fernández, Amalia Rueda Cid, Javier Calvo Catalá (Hospital Gral.
De Valencia); Rafael Benito Melero González, Francisco Maceiras, Nair Pérez, Ceferino Barbazán, José María Pego, Irene Altabás, John Guzman (Complejo Hospitalario. Universidad de Vigo); Paula Valentina Estrada Alarcón, Vanessa Andrea Navarro Angeles (Hospital Moises Broggi); Patricia Moya Alvarado, Héctor Corominas, Iván Castellví, Berta Magallares, Ana Milena Millán (Hospital Santa Creu i Sant Pau); Ana F. Cruz Valenciano, Félix Cabero del Pozo, Ana Belén Rodríguez Cambrón, Cristina Maciá Villa, Eva Álvarez de Andrés (Hospital Severo Ochoa); Antonio Juan Mas, Inmaculada Ros Vilamajó, Mónica Ibáñez Barcelo, Elide Toniolo, Ana Paula Cacheda (Hospital Son Llatzer); María Sagrario Bustabad Reyes, María García González, Vanesa Hernández Hernández (Hospital Universitario Canarias); Jaime Calvo Allen (Hospital Universitario.
De Araba); Eugenio de Miguel Mendieta, Irene Monjo Henri (Hospital Universitario La Paz); Miren Uriarte-Ecenarro, Cristina Valero Martínez, Esther F. Vicente Rabaneda (Hospital Universitario La Princesa); Carlos García Porrúa, Noelia Álvarez Rivas, Tomás Ramón Vázquez Rodríguez, José Alberto Miranda Filloy, Amalia Sánchez-Andrade Fernández (Hospital Universitario Lucus Augusti); Miguel Ángel González-Gay (Hospital Universitario Marqués de Valdecilla); Carlos Galisteo Lencastre Da Veiga, Joan Calvet Fontova (Hospital Universitario Parc Tauli); María Jesús García Villanueva, Carmen Larena Grijalba, Marina Tortosa Cabañas, Patricia Morán Álvarez, Marta Serrano Warleta, Aliuska Palomeque Vargas (Hospital Univ.
Ramón y Cajal); Noemí Garrido, Alberto Ruíz Román, Clara Aguilera Cros, Alejandro Muñoz Jiménez (Hospital Universitario Virgen del Rocío); José A. Román Ivorra, Carmen Riesco Bárcena, Anderson Huaylla (Hospital Universitario Politécnico La Fe); Itziar Calvo Zorrilla (Hospital Universitario Basurto); Judit Lluch (Hospital Universitario de Bellvitge); Jesús A. Valero Jaimes, Luis López Domínguez, Cesar Antonio Egues Dubuc (Hospital Universitario Donosti); Lucia Silva Fernández (Complexo Hospitalario Univ. de A Coruña).
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T00:57:50.267584+00:00
DOI: 10.3390/nu17203291 · PMC12567256